Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial
Francisco M. Marty(Brigham and Women's Hospital), Amanda Peppercorn(GlaxoSmithKline (United States)), Petr Husa(Masaryk University), Helen Watson(GlaxoSmithKline (United Kingdom)), Carol L. Clark(Beaumont Hospital, Royal Oak), Denise Shortino(Triangle), Sandeep K. Gupta(M.V. Hospital and Research Centre), Marianne J. Chapman(Royal Adelaide Hospital), Eduardo Rodríguez-Noriega(Hospital Civil de Guadalajara), Joan Vidal-Puigserver(Hospital Universitario Son Espases), Phillip J. Yates(GlaxoSmithKline (United Kingdom)), Denis Garot(Centre Hospitalier Universitaire de Tours), Frédérique Jacobs(Université Libre de Bruxelles), Esperanza Merino(Universitat de Miguel Hernández d'Elx)
Cited by 104
Related Papers
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
|The Lancet|2007|689
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
|Journal of Viral Hepatitis|2014|484
Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction
|Journal of the American College of Cardiology|2018|464
Breakthrough Zygomycosis after Voriconazole Treatment in Recipients of Hematopoietic Stem-Cell Transplants
|New England Journal of Medicine|2004|425